Coupe, Nicholas
Guo, Lina
Bridges, Esther
Campo, Leticia
Espinosa, Olivia
Colling, Richard
Marshall, Andrea
Nandakumar, Ashwin
van Stiphout, Ruud
Buffa, Francesca M.
Corrie, Pippa G.
Middleton, Mark R.
Macaulay, Valentine M.
Funding for this research was provided by:
Cancer Research UK (CRUKDF 0317-NC)
Oxfordshire Health Services Research Committee (EC/1150)
Oxford Experimental Cancer Medicine Centre
Oxford pathLAKE Centre of Excellence (104689)
ARTICULATE PRO (Al AWARD02269)
NIHR Cambridge Biomedical Research Centre (BRC-1215-22214)
Cancer Research UK CRUK Oxford Centre, Clinical and non-Clinical Academic Training Program
NIHR Oxford Biomedical Research Centre
Article History
Accepted: 5 December 2022
First Online: 21 December 2022
Declarations
:
: Mouse work was conducted in accordance with the UK Home Office guidelines, under project licence of Professor Adrian Harris (PPL 30 /3197). Human ethical approval is not applicable for this study.
: All co-authors have provided written consent for this work to be published.
: Not applicable.
: MRM has received grants from Roche, AstraZeneca and GSK; personal and other fees from Novartis, BMS, Merck/MSD and BioLineRx; grants, personal and other fees from Immunocore; other fees from Pfizer and Regeneron; personal fees and non-financial support from Replimune; personal fees from Kineta and Silicon Therapeutics; grants from GRAIL outside the submitted work. VMM is a consultancy board member for Boehringer Ingelheim. PGC has received grants from Roche, Celgene and Pierre Fabre, speaker/consultancy fees from Novartis, BMS, Merck Sharpe & Dohme, Microbiotica The other authors have no conflicts to declare.